The levels of serum testosterone (T), luteinizing hormone (LH) and follicle-stimulating hormone (FSH) in rat serum were detected by using an enzyme-linked immunoassay (ELISA)
Brightens skin for a radiant complexion
In contrast, in intestinal cells and certain brain regions, prohormone convertase 1/3 (PC1/3) processes proglucagon to generate GLP-1, intervening peptide-2 (IP-2), and GLP-2
Executive Vice President & President, Lilly Cardiometabolic Health, Eli Lilly and Company Why this matters 1 Triple agonist = next-gen metabolic therapy Mimics GLP-1, GIP, and glucagon multi-pathway metabolic control 2 Diabetes + obesity convergence Simultaneous A1C + weight control = major unmet need solved 3 Competitive landscape shift Raises the bar vs GLP-1 mono & dual incretin therapies 4 No plateau signal is critical Suggests longer-term sustained efficacy Safety profile (expected class effects) Nausea, diarrhea, vomiting (dose-escalation phase) Discontinuation rates relatively low (25%) My takeaway 1 Metabolic disease treatment is entering multi-hormone era 2 Obesity + diabetes becoming one therapeutic category 3 Efficacy approaching bariatric-level outcomes 4 Sets new benchmark for Novo Nordisk and competitors Bottom line: Retatrutide isnt just competing Its redefining how we treat metabolic disease at the systems level #Diabetes #Obesity #GLP1 #Biotech #ClinicalTrials #Pharma #Innovation To view or add a comment, sign in 2,706 followers
We're trying to decide how we define it before we do our literature review
